Stock market today: Dow in fresh record close as Powell signals rate cut incoming
On Wednesday, Intensity Therapeutics , Inc. (NASDAQ:INTS), currently trading at $0.39, received a reiterated Speculative Buy rating and a $4.00 price target from Benchmark. The company, known for its clinical pipeline, recently disclosed its financial outcomes for the first quarter of 2025, alongside a corporate update. According to InvestingPro data, analyst price targets for the stock range from $4 to $15, suggesting significant upside potential from current levels.
Intensity Therapeutics reported a quarterly loss of $3.3 million, equating to ($0.19) per share. This performance marks an improvement compared to the loss of $4.6 million, or ($0.34) per share, recorded in the same period the previous year. The company’s research and development (R&D) expenditures for the quarter were $2.2 million, with additional overhead costs amounting to $1.2 million.
The company’s R&D activities in the first quarter of 2025 included significant progress in its clinical studies. Notably, the European Medicines Agency (EMA) granted authorization for Intensity to begin enrolling patients in France for their Invincible-4 study. This development complements the activation of eight additional study sites in Switzerland, where several patients have already been treated.
Benchmark’s analyst highlighted these advancements in the company’s clinical pipeline as a basis for maintaining the Speculative Buy rating and the price target for Intensity Therapeutics. The firm’s continued endorsement reflects its view on the potential of Intensity’s ongoing research and development efforts.
In other recent news, Intensity Therapeutics, Inc. has been the focus of several significant updates. The company reported a net loss of $16.3 million for 2024, translating to a loss of $1.17 per share, contrasting with the previous year’s net loss of $11.9 million. This financial disclosure comes as the company continues its efforts in advancing its lead pipeline program, INT230-6, which is currently in Phase 3 trials for soft tissue sarcoma. To support ongoing clinical trials, Intensity Therapeutics has announced a public offering aiming to raise approximately $2.35 million, with proceeds intended for patient enrollment in the INVINCIBLE-4 study and other corporate purposes.
Additionally, Brookline Capital Markets downgraded Intensity Therapeutics from a Buy to a Hold rating, citing concerns over the company’s financial runway and the need for additional funding. Despite this, Benchmark has maintained its Speculative Buy rating with a $4.00 price target, reflecting continued interest in the company’s potential. The company is actively engaged in multiple clinical trials, including the INVINCIBLE-3 study for soft tissue sarcoma and the INVINCIBLE-4 study for triple-negative breast cancer. These developments highlight the company’s ongoing efforts to advance its clinical programs amidst financial challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.